News

De Ceunynck Radiotherapy will be present at the BHPA meeting in February. Our invited speaker Dr. M. Palacios will speak about “MR-guided Adaptive Radiation Therapy with the MRIdian: 2 years of clinical experience”

If you would to schedule a meeting with us at this meeting, please contact us.

IQM: the next generation of Radiation Therapy Verification

De Ceunynck Radiotherapy will be present at the ABRO-BVRO Autumn meeting 2017 in Brussels October 20 - 21

Come by the De Ceunynck Radiotherapy booth to learn about the MRIdian Linac system. On Saturday morning, October 21st, Frank J. Lagerwaard MD. PhD., will be hosting an Update Lecture with the title "One year experience with clinical MRgRT using the MRIdian", discussing the more than 1 year of clinical experience of VUmc Amsterdam with MR guided RadioTherapy and SMART (Stereotactic MR-guided Adaptive RadioTherapy)

If you would like to schedule an appointment with us at this meeting, please contact us.

I look forward to seeing you at the ABRO-BVRO Autumn meeting in Brussels!

ViewRay and De Ceunynck Radiotherapy will be present during ASTRO 2017. The ASTRO Annual Meeting is the world's most important meeting for the radiation oncology community, with more than 11,000 people attending each year and it is now just a few weeks away.

As you would expect ViewRay and De Ceunynck Radiotherapy will be attending this event and you can find us at the ViewRay stand #1317.

If you would like to learn more about the MRIdian system, hear from expert users and enjoy the in-booth presentations please come along and say hello. You can also attend the Industry Expert Theater session on Tuesday, September 26 at 12:30pm which is in Theater 1.

ViewRay will host a Reception on Sunday, 24 September at 18:30. If you would like to attend please let me know so I can register you.

I look forward to seeing you at ASTRO 2017 in San Diego!

If you would like a personal presentation or some face to face time with ViewRay experts then please get in touch.

Presentations Also Highlighted Speed and Benefit of On-Table Adaptive Therapy in Routine Clinical Use May 15, 2017

CLEVELAND, May 15, 2017 — ViewRay, Inc. (Nasdaq: VRAY) announced today highlights from ESTRO 36, the annual meeting of the European Society for Radiotherapy and Oncology, which featured broad clinical experience with the company’s MRIdian System, including compelling early data on its use in pancreatic cancer.